Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Day One Biopharmaceuticals Inc (DAWN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: DAWN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $28
1 Year Target Price $28
| 4 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.03% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 655.81M USD | Price to earnings Ratio - | 1Y Target Price 28 |
Price to earnings Ratio - | 1Y Target Price 28 | ||
Volume (30-day avg) 8 | Beta -1.3 | 52 Weeks Range 6.08 - 16.76 | Updated Date 06/30/2025 |
52 Weeks Range 6.08 - 16.76 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.65 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -42.66% | Operating Margin (TTM) -133.5% |
Management Effectiveness
Return on Assets (TTM) -27.81% | Return on Equity (TTM) -17.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 185711167 | Price to Sales(TTM) 4.05 |
Enterprise Value 185711167 | Price to Sales(TTM) 4.05 | ||
Enterprise Value to Revenue 1.15 | Enterprise Value to EBITDA -7.18 | Shares Outstanding 101362000 | Shares Floating 71940998 |
Shares Outstanding 101362000 | Shares Floating 71940998 | ||
Percent Insiders 17.03 | Percent Institutions 94.47 |
Analyst Ratings
Rating 3 | Target Price 28 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Day One Biopharmaceuticals Inc
Company Overview
History and Background
Day One Biopharmaceuticals, founded in 2018, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for cancers. Their focus is on pediatric populations.
Core Business Areas
- Oncology Therapeutics: Focuses on the discovery, development, and commercialization of therapies for childhood cancers.
Leadership and Structure
The leadership team includes Jeremy Bender (CEO). The structure is typical of a clinical-stage biotech company, with research, clinical development, and commercial functions.
Top Products and Market Share
Key Offerings
- Tovorafenib (DAY101): A highly selective, brain-penetrant RAF kinase inhibitor being developed for relapsed or progressive pediatric low-grade glioma (pLGG). Data indicates positive clinical trials. Market share is developing and will depend on FDA approval and commercialization. Competitors include drugs used off-label, surgery, and radiation.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and competitive, with a growing emphasis on targeted therapies and personalized medicine. Pediatric oncology is a specialized niche.
Positioning
Day One Biopharmaceuticals is positioned as a leader in pediatric oncology, focused on targeted therapies for difficult-to-treat cancers. Their advantage lies in their lead asset, Tovorafenib.
Total Addressable Market (TAM)
The TAM for pediatric oncology therapeutics is substantial. Day One aims to capture a significant portion of the pLGG market and potentially expand to other indications.
Upturn SWOT Analysis
Strengths
- Promising lead asset (Tovorafenib)
- Focus on underserved pediatric oncology market
- Experienced management team
- Strong intellectual property position
Weaknesses
- Limited commercial infrastructure
- Reliance on a single lead asset
- High cash burn rate
- Risk associated with clinical trials and regulatory approval
Opportunities
- Potential FDA approval and commercialization of Tovorafenib
- Expansion into other pediatric oncology indications
- Strategic partnerships with larger pharmaceutical companies
- Further development of pipeline assets
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory setbacks
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- MRTX
- BAYRY
Competitive Landscape
Day One operates in a competitive landscape with both established pharmaceutical companies and emerging biotech firms. Their success depends on differentiating their therapies and securing regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to clinical trial progress and fundraising activities.
Future Projections: Future growth depends on the successful development and commercialization of Tovorafenib and other pipeline assets. Analyst estimates vary depending on these factors.
Recent Initiatives: Recent initiatives include advancing Tovorafenib through clinical trials and preparing for potential commercialization.
Summary
Day One Biopharmaceuticals is a promising clinical-stage company with a focus on pediatric oncology, particularly with their lead asset, Tovorafenib. They are well-positioned to address an unmet need in the market if Tovorafenib receives FDA approval. The company needs to manage its cash burn and navigate the regulatory landscape effectively, facing competition from larger pharmaceutical companies and potential clinical trial setbacks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Day One Biopharmaceuticals Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2021-05-27 | CEO, President & Director Dr. Jeremy Bender M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 181 | Website https://dayonebio.com |
Full time employees 181 | Website https://dayonebio.com | ||
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.